Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver

Park, Huiyul; Yoon, Eileen L.; Kim, Mimi; Kim, Junghwan; Cho, Seon; Jun, Dae Won; Nah, Eun‐Hee

doi:10.3390/jcm10194625

Cited by 6 publications

(3 citation statements)

References 19 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The global burden of NAFLD is on the rise with the increasing prevalence of obesity [1,3,4]. Nonalcoholic steatohepatitis (NASH) is a progressive form of NAFLD that occurs in close association with obesity, type 2 diabetes, and metabolic syndrome [3,5,6]. No approved pharmacological options are currently available for patients with NASH; therefore, the demand for developing new therapeutic agents is still high.…”

Section: Introductionmentioning

confidence: 99%

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease

et al. 2023

Self Cite

View full text Add to dashboard Cite

Preclinical data have shown that the herbal extract, ALS-L1023, from Melissa officinalis reduces visceral fat and hepatic steatosis. We aimed to assess the safety and efficacy of ALS-L1023 as the treatment of non-alcoholic fatty liver disease (NAFLD). We conducted a 24-week randomized, double-blind, placebo-controlled 2a study in patients with NAFLD (MRI-proton density fat fraction [MRI-PDFF] ≥ 8% and liver fibrosis ≥ 2.5 kPa on MR elastography [MRE]) in Korea. Patients were randomly assigned to 1800 mg ALS-L1023 (n = 19), 1200 mg ALS-L1023 (n = 21), or placebo (n = 17) groups. Efficacy endpoints included changes in liver fat on MRI-PDFF, liver stiffness on MRE, and liver enzymes. For the full analysis set, a relative hepatic fat reduction from baseline was significant in the 1800 mg ALS-L1023 group (−15.0%, p = 0.03). There was a significant reduction in liver stiffness from baseline in the 1200 mg ALS-L1023 group (−10.7%, p = 0.03). Serum alanine aminotransferase decreased by −12.4% in the 1800 mg ALS-L1023 group, −29.8% in the 1200 mg ALS-L1023 group, and −4.9% in the placebo group. ALS-L1023 was well tolerated and there were no differences in the incidence of adverse events among the study groups. ALS-L1023 could reduce hepatic fat content in patients with NAFLD.

show abstract

Section: Introductionmentioning

confidence: 99%

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported the usefulness of imaging examinations such as computed tomography (CT) and magnetic resonance (MR) imaging for noninvasively evaluating liver fibrosis [ 1 , 2 , 3 , 4 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ]. Hepatic extracellular volume fraction (fECV) analysis with contrast-enhanced CT is another noninvasive method for evaluating liver fibrosis.…”

Section: Introductionmentioning

confidence: 99%

Noninvasive Liver Fibrosis Staging: Comparison of MR Elastography with Extracellular Volume Fraction Analysis Using Contrast-Enhanced CT

Yano

Onishi

Tsuboyama

et al. 2022

JCM

View full text Add to dashboard Cite

Purpose: To compare the accuracy of liver fibrosis staging with MR elastography and of staging with extracellular volume fraction (fECV) analysis using contrast-enhanced CT. Methods: This retrospective study included 60 patients who underwent both MR elastography and contrast-enhanced CT before liver surgery between October 2013 and July 2020. Two radiologists independently measured liver stiffness of MR elastography and fECV of CT images. Accuracy for liver fibrosis staging was assessed using receiver operating characteristic (ROC) analysis. Correlations between liver stiffness or fECV and liver fibrosis were also evaluated by means of the Spearman rank correlation coefficient. Results: The areas under the ROC curves for MR elastography for each stage differentiation of ≥F1 (0.85, 0.82 for the two radiologists), ≥F2 (0.88, 0.89), ≥F3 (0.87, 0.86), and F4 (0.84, 0.83) were greater than those for fECV analysis with CT (0.64, p = 0.06, 0.69, p = 0.2; 0.62, p < 0.005, 0.63, p < 0.005; 0.62, p < 0.005, 0.62, p < 0.01; and 0.70, p = 0.08, 0.71, p = 0.2, respectively). The correlation coefficients between liver stiffness and liver fibrosis in A0 (0.67, 0.69 for the two radiologists), A1 (0.64, 0.66) and A2 group (0.58, 0.51) were significantly higher than those between fECV and liver fibrosis (0.28, 0.30; 0.27, 0.31; and 0.23, 0.07; p < 0.05 for all comparisons). Conclusion: MR elastography allows for more accurate liver fibrosis staging compared with fECV analysis with CT. In addition, MR elastography may be less affected than fECV analysis by the inflammatory condition.

show abstract

“…MAFLD is known to be better at stratifying those at a higher risk for advanced liver fibrosis and overall mortality than the previous NAFLD definition. 2 - 4 Due to the exclusive nature of the NAFLD definition, we could not call comorbid hepatic steatosis as NAFLD when it co-exists with viral hepatitis, for example. However, MAFLD includes those patients with other chronic liver diseases permitting dual etiologies in a same patient.…”

mentioning

confidence: 99%

Waiting for Multi-Stakeholders’Consensus Position Statement on New Nonalcoholic Fatty Liver Disease Nomenclature

Yoon

Jun

2022

Gut and Liver

Self Cite

View full text Add to dashboard Cite

Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver

Cited by 6 publications

References 19 publications

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease

Noninvasive Liver Fibrosis Staging: Comparison of MR Elastography with Extracellular Volume Fraction Analysis Using Contrast-Enhanced CT

Waiting for Multi-Stakeholders’Consensus Position Statement on New Nonalcoholic Fatty Liver Disease Nomenclature

Contact Info

Product

Resources

About